Helix BioPharma Corp. Announces Board of Directors Changes
Vancouver, British Columbia — August 14, 2026 — Leads & Copy — Helix BioPharma Corp., a clinical-stage oncology company, announced immediate changes to its Board of Directors. Mr. Janusz Grabski has resigned from the Board, and Thomas Mehrling, M.D., Ph.D., the company’s Chief Executive Officer, has been appointed as a director. This appointment is in accordance with the Board nomination right granted to Laevoroc Immunology AG in connection with Helix BioPharma’s 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
These changes are intended to ensure the Board can continue to meet Helix BioPharma’s evolving governance and capital markets requirements. The Board aims to maintain a composition and experience level necessary to support the company’s clinical development and broader corporate objectives.
The Board expressed its gratitude to Mr. Grabski for his service and contributions to Helix BioPharma, wishing him success in his future endeavors.
Helix BioPharma Corp. is dedicated to developing therapies for underserved patient populations dealing with difficult-to-treat cancers. The company’s lead pipeline candidate is L-DOS47, an antibody-enzyme conjugate currently in clinical development as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, an oral immune checkpoint modulator intended for post-transplant leukemia relapse, which is in the pre-Investigational New Drug (IND) phase, and GEMCEDA™, a gemcitabine prodrug for advanced solid tumors, also in the pre-IND stage.
Helix BioPharma’s common shares are traded on the Toronto Stock Exchange under the ticker HBP, quoted on the OTC Pink Market under HBPCD, and listed on the Frankfurt Stock Exchange under HBP0.
Source: Helix BioPharma Corp.
Share this story:
